Business Description
Amylyx Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US03237H1014
Description
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 91.31 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.54 | |||||
| Beneish M-Score | -5.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y Total Revenue Growth Rate Estimate | -87.18 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.25 | |||||
| 9-Day RSI | 26.03 | |||||
| 14-Day RSI | 34.57 | |||||
| 3-1 Month Momentum % | 116.79 | |||||
| 6-1 Month Momentum % | 238.1 | |||||
| 12-1 Month Momentum % | -61.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.55 | |||||
| Quick Ratio | 4.55 | |||||
| Cash Ratio | 4.35 | |||||
| Days Inventory | 86.76 | |||||
| Days Sales Outstanding | 35.51 | |||||
| Days Payable | 30.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.8 | |||||
| Shareholder Yield % | 0.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 31.81 | |||||
| Operating Margin % | -108.45 | |||||
| Net Margin % | -132.05 | |||||
| FCF Margin % | -48.65 | |||||
| ROE % | -79.41 | |||||
| ROA % | -65.38 | |||||
| ROIC % | -516.65 | |||||
| 3-Year ROIIC % | 91.88 | |||||
| ROC (Joel Greenblatt) % | -1401.74 | |||||
| ROCE % | -64.92 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.54 | |||||
| PB Ratio | 1.54 | |||||
| Price-to-Tangible-Book | 1.44 | |||||
| EV-to-EBIT | -0.33 | |||||
| EV-to-EBITDA | -0.33 | |||||
| EV-to-Revenue | 0.36 | |||||
| EV-to-Forward-Revenue | 1.84 | |||||
| EV-to-FCF | -0.74 | |||||
| Price-to-Net-Current-Asset-Value | 1.48 | |||||
| Price-to-Net-Cash | 1.57 | |||||
| Earnings Yield (Greenblatt) % | -303.03 | |||||
| FCF Yield % | -31.62 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AMLX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amylyx Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 196.485 | ||
| EPS (TTM) ($) | -3.82 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 130.4 | ||
| 14-Day RSI | 34.57 | ||
| 14-Day ATR ($) | 0.413981 | ||
| 20-Day SMA ($) | 5.096 | ||
| 12-1 Month Momentum % | -61.41 | ||
| 52-Week Range ($) | 1.575 - 19.9488 | ||
| Shares Outstanding (Mil) | 68.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amylyx Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amylyx Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Amylyx Pharmaceuticals Inc Frequently Asked Questions
What is Amylyx Pharmaceuticals Inc(AMLX)'s stock price today?
The current price of AMLX is $4.12. The 52 week high of AMLX is $19.95 and 52 week low is $1.58.
When is next earnings date of Amylyx Pharmaceuticals Inc(AMLX)?
The next earnings date of Amylyx Pharmaceuticals Inc(AMLX) is 2025-02-21 Est..
Does Amylyx Pharmaceuticals Inc(AMLX) pay dividends? If so, how much?
Amylyx Pharmaceuticals Inc(AMLX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers